Neumora Therapeutics, Inc. NMRA
0.68
(0.02)
(2.86%)
as of 25 Sep
- Market cap
- $135.3M
- P/E
- 0.0×
Follow NMRA
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | |
|---|---|---|---|---|---|
Current Ratio |
5.87 | 10.51 | 19.05 | 16.37 | 17.85 |
Net Debt/EBITDA |
0.53 | 1.15 | 1.78 | 2.70 | 5.17 |
Debt/Assets |
28.54% | 0.00% | 0.00% | 1.19% | 0.48% |
Debt/Equity |
0.53 | 0.00 | 0.00 | 0.01 | 0.01 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.87 | 0.75 | 0.69 | 0.88 | 0.32 |
Capex/Depreciation |
(0.14) | 0.00 | 0.04 | 4.48 | 0.00 |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (121.21%) | (64.48%) | (2,122.97%) | 33.91% | 0.00% | |
| (93.28%) | (59.96%) | (51.15%) | (30.60%) | 0.00% | |
ROIC |
0.00% | 0.00% | (1,043.87%) | (283.30%) | 0.00% |
Return on Tangible Assets |
(149.83%) | (85.45%) | (51.86%) | (35.70%) | (59.87%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(1.26) | (1.15) | (2.51) | (4.24) | (0.50) |
Cash per Share |
1.12 | 1.94 | 6.98 | 13.67 | 2.69 |
Shareholders Equity per Share |
0.64 | 1.80 | 7.21 | 14.59 | 2.66 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.64 | 1.80 | 7.21 | 14.59 | 2.66 |
Free Cash Flow |
(206.22) | (182.94) | (163.39) | (115.41) | (75.42) |
Working Capital |
158.09 | 284.17 | 453.17 | 364.26 | 392.33 |
Capital Expenditures |
0.22 | — | (0.12) | (0.51) | (0.82) |
Net Current Asset Value |
103.36 | 284.15 | 451.16 | 358.56 | 390.94 |
| Other line items | |||||
Quick Ratio |
5.62 | 10.33 | 18.08 | 15.70 | 17.59 |
Depreciation/Fixed assets |
(37.92) | (4.46) | (1.72) | (0.05) | 0.38 |
Cash ROIC |
(60.56%) | (30.89%) | (17.88%) | (15.16%) | (9.74%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 385.71 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.26) | (1.15) | (2.51) | (4.22) | (0.50) |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | 0.00 |
Average Receivables |
— | — | — | 0.56 | — |
Average Payables |
3.34 | 1.82 | 3.74 | 4.39 | — |
Average Assets |
254.01 | 406.58 | 461.21 | 427.77 | — |
Average Common Equity |
195.47 | 378.07 | 11.11 | (386.04) | — |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates